Stereoselective single-dose kinetics of citalopram and its metabolites in rats

被引:24
作者
Kugelberg, FC [1 ]
Carlsson, B
Ahlner, J
Bengtsson, F
机构
[1] Linkoping Univ, Fac Hlth Sci, Div Clin Pharmacol, Dept Med & Care, SE-58185 Linkoping, Sweden
[2] Natl Board & Forens Med, Dept Forens Chem, Linkoping, Sweden
[3] Danish Univ Pharmaceut Sci, Dept Pharmacol, Copenhagen, Denmark
关键词
citalopram; enantiomer; HPLC; metabolites; pharmacokinetics; rat; toxicokinetics;
D O I
10.1002/chir.10266
中图分类号
R914 [药物化学];
学科分类号
100701 [药物化学];
摘要
The single-dose kinetics of the enantiomers of citalopram (CIT) and its metabolites, demethylcitalopram (DCIT) and didemethylcitalopram (DDCIT), were investigated after administration of 10, 20, or 100 mg/kg (s.c.) rac-CIT to rats. Samples from serum and two brain regions were collected 1, 3, 10, or 20 h postdose for HPLC analysis. In the 100 mg/kg rats, the enantiomeric (S/R) serum concentration ratios of CIT decreased during the study period (0.93 at 1 h vs. 0.59 at 20 h; P < 0.001). In the 10 and 20 mg/kg rats, the decrease in serum S/R CIT ratios was not so evident as in the 100 mg/kg rats. In all three groups the S/R CIT ratio was almost the same in the brain as in serum, although both CIT enantiomer levels in the brain were found to be 5-10 times higher than the levels in serum. The serum and brain metabolite levels were low in the 10 and 20 mg/kg rats, whereas the levels increased during the study period in the 100 mg/kg rats. In conclusion, the CIT enantiomers were shown for the first time to be stereoselectively metabolized after single-dose administration to rats, as previously shown in steady-state dosing studies in humans and rats. (C) 2003 Wiley-Liss, Inc.
引用
收藏
页码:622 / 629
页数:8
相关论文
共 41 条
[1]
Dynamic and kinetic effects of chronic citalopram treatment in experimental hepatic encephalopathy [J].
Apelqvist, G ;
Wikell, C ;
Carlsson, B ;
Hjorth, S ;
Bergqvist, PBF ;
Ahlner, J ;
Bengtsson, F .
CLINICAL NEUROPHARMACOLOGY, 2000, 23 (06) :304-317
[2]
THE IMPACT OF TIME AFTER PORTACAVAL-SHUNT IN THE RAT ON BEHAVIOR, BRAIN-SEROTONIN, AND BRAIN AND MUSCLE HISTOLOGY [J].
BENGTSSON, F ;
BUGGE, M ;
BRUN, A ;
FALCK, B ;
HENRIKSSON, KG ;
NOBIN, A .
JOURNAL OF THE NEUROLOGICAL SCIENCES, 1988, 83 (01) :109-122
[3]
Effect of citalopram on brain serotonin release in experimental hepatic encephalopathy: Implications for thymoleptic drug safety in liver insufficiency [J].
Bergqvist, PBF ;
Wikell, C ;
Hjorth, S ;
Apelqvist, G ;
Bengtsson, F .
CLINICAL NEUROPHARMACOLOGY, 1997, 20 (06) :511-522
[4]
Bezchlibnyk-Butler K, 2000, J PSYCHIATR NEUROSCI, V25, P241
[5]
Metabolism of the newer antidepressants - An overview of the pharmacological and pharmacokinetic implications [J].
Caccia, S .
CLINICAL PHARMACOKINETICS, 1998, 34 (04) :281-302
[6]
Enantioselective analysis of citalopram and metabolites in adolescents [J].
Carlsson, B ;
Olsson, G ;
Reis, M ;
Wålinder, J ;
Nordin, C ;
Lundmark, J ;
Scordo, MG ;
Dahl, ML ;
Bengtsson, F ;
Ahlner, J .
THERAPEUTIC DRUG MONITORING, 2001, 23 (06) :658-664
[7]
Augmentation with a 5-HT1A but not a 5-HT1B receptor antagonist critically depends on the dose of citalopram [J].
Cremers, TIFH ;
de Boer, P ;
Liao, Y ;
Bosker, FJ ;
den Boer, JA ;
Westerink, BHC ;
Wikström, HV .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2000, 397 (01) :63-74
[8]
Druid H, 1997, J FORENSIC SCI, V42, P79
[9]
Foglia JP, 1997, PSYCHOPHARMACOL BULL, V33, P109
[10]
Fredricson OK, 1982, PROG NEUROPSYCHOPHAR, V6, P311